Drug Search Results
More Filters [+]

Deuruxolitinib

Alternative Names: deuruxolitinib, ctp-543, ctp543, ctp 543
Latest Update: 2024-10-25
Latest Update Note: News Article

Product Description

Deuruxolitinib (CTP-543) is a deuterium-modified analogue of the JAK inhibitorÊruxolitinib. It is an oral inhibitor that inhibits JAK1/2. The chemical structure, and its use in hair loss disorders are claimed in patent WO2017192905A1 (Sourced from: https://www.guidetoimmunopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=11410)

Mechanisms of Action: JAK Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: Breakthrough Therapy - Alopecia|Alopecia Areata *

Approval Status: Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Concert
Company Location: LEXINGTON MA 02421
Company CEO: Roger D. Tung
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Deuruxolitinib

Countries in Clinic: Canada, France, Germany, Hungary, Poland, Spain, United States

Active Clinical Trial Count: 14

Highest Development Phases

Phase 3: Alopecia Areata

Phase 1: Healthy Volunteers|Kidney Diseases|Other

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CP543.5001

P3

Active, not recruiting

Alopecia Areata

2025-05-01

2021-002365-18

P3

Active, not recruiting

Alopecia Areata

2024-09-06

CP543.5002

P3

Completed

Alopecia Areata

2024-07-18

CP543.2004

P2

Completed

Alopecia Areata

2023-05-15

Recent News Events